No hype, no protocols, no miracle claims. Just plain-language summaries of what the research actually shows, where each peptide stands with the FDA in 2026, and how to find legitimate care.
No, and the fuller answer matters. Why BPC-157 sits "under review" in 2026 and what that actually means for you.
Read the article →FDA-approved vs compounded vs "research only", a plain-English map of what's actually legal, and why it depends on the specifics.
Read the article →Not FDA-approved here, approved abroad, and caught in the shifting 2026 reclassification. The honest status.
Read the article →Why "not for human consumption" isn't a shield, how the FDA's "intended use" logic works, and why it's often a red flag.
Read the article →The scheduled advisory-committee review, what's genuinely at stake, and what to watch, without the speculation.
Read the article →How they differ on paper, what the research can and can't say, and why there's no evidence-based "winner", minus the protocols.
Read the article →Shared roots, different emphasis (anxiety vs cognition), and the same unsettled US status, minus the nootropic-forum hype.
Read the article →Two different mechanisms and two different regulatory histories, including the one detail that sets sermorelin apart.
Read the article →Why they're discussed as a pair, how their mechanisms actually differ, and why "discussed together" isn't "proven."
Read the article →Two approved, evidence-backed medications with different mechanisms, and why the choice between them is a clinical decision, not a shopping one.
Read the article →Why there's no "generic Ozempic," where the compounded market came from, and how to tell a legitimate option from a gamble.
Read the article →Why the human safety data is thin, what that uncertainty actually means, and the separate risk that has nothing to do with the molecule.
Read the article →Approved medicines vs barely-studied research compounds, and the three factors (evidence, source, oversight) that actually drive safety.
Read the article →It's everywhere in recovery circles. We stepped back from the noise to look at what scientists have really studied.
Read the article →The copper peptide shows up in serums and recovery talk alike. There's real research, and a wide gap to systemic therapy.
Read the article →A peptide first developed in Russia for anxiety and focus. A measured look at the (mostly early) evidence.
Read the article →Unlike the research peptides here, GLP-1s are FDA-approved with large trials behind them. Here's why that matters.
Read the article →It's the rare peptide that was once FDA-approved, then left the shelf. That history shapes where it stands today.
Read the article →A peptide encoded in your mitochondria, studied for metabolism and exercise. Genuinely novel biology, early evidence.
Read the article →What TB-500 is, what the research has explored for recovery, and two things worth knowing, including its anti-doping status.
Read the article →What Semax is, the largely-Russian research picture, and why "longer track record" still doesn't mean "proven here."
Read the article →The usual names (BPC-157, TB-500, GHK-Cu), what the research can and can't back up, and the honest through-line.
Read the article →The compounds people ask about (Selank, Semax), why they're not substitutes for real care, and the honest framing.
Read the article →Sermorelin, ipamorelin, CJC-1295, and tesamorelin, the map, and the approved-vs-research line that matters most.
Read the article →The approved options, the messy compounded market, and why the fundamentals (approved product, licensed provider) haven't changed.
Read the article →What legitimate care looks like, the gray-market red flags to walk away from, and how to make the first connection safely.
Read the article →No articles match — try a different search or category.